Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Total Non-Current Liabilities: 2023-2024

Historic Total Non-Current Liabilities for BioLineRx (BLRX) over the last 2 years, with Dec 2024 value amounting to $10.0 million.

  • BioLineRx's Total Non-Current Liabilities fell 61.61% to $7.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was $7.7 million, marking a year-over-year decrease of 61.61%. This contributed to the annual value of $10.0 million for FY2024, which is 26.79% up from last year.
  • Latest data reveals that BioLineRx reported Total Non-Current Liabilities of $10.0 million as of FY2024, which was up 26.79% from $7.9 million recorded in FY2023.
  • BioLineRx's Total Non-Current Liabilities' 5-year high stood at $10.0 million during FY2024, with a 5-year trough of $7.9 million in FY2023.
  • For the 2-year period, BioLineRx's Total Non-Current Liabilities averaged around $9.0 million, with its median value being $9.0 million (2023).
  • Data for BioLineRx's Total Non-Current Liabilities shows a peak YoY increased of 26.79% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows BioLineRx's Total Non-Current Liabilities stood at $7.9 million in 2023, then increased by 26.79% to $10.0 million in 2024.